MedTrace Logo

Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents

NCT05965401 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-05-20

No results posted yet for this study

Summary

This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or GLAD-PC guided prescribing (control intervention).

Conditions

  • Depression in Adolescence

Interventions

OTHER

Pharmacogenetic-guided dosing

SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.

OTHER

GLAD-PC guided dosing

SSRI dosing based on GLAD-PC clinical practice guidelines

Sponsors & Collaborators

  • University of Alberta

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Chad Bousman, PhD · University of Calgary

  • Amanda Newton, PhD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2025-05-02
Completion
2025-05-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05965401 on ClinicalTrials.gov